Adjuvant interferon-alpha for melanoma revisited: News from old and new studies
Open Access
- 1 December 2001
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 12 (12) , 1663-1666
- https://doi.org/10.1023/a:1013592219007
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trialThe Lancet, 2001
- Adjuvant interferon alpha 2b in high risk melanoma – the Scottish studyBritish Journal of Cancer, 2001
- High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801Journal of Clinical Oncology, 2001
- The AJCC staging proposal for cutaneous melanoma: Comments by the EORTC Melanoma GroupAnnals of Oncology, 2001
- High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190Journal of Clinical Oncology, 2000
- A new American Joint Committee on Cancer staging system for cutaneous melanomaCancer, 2000
- Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastasesThe Lancet, 1998
- Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.Journal of Clinical Oncology, 1998
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- Results of adjuvant interferon study In WHO melanoma programmeThe Lancet, 1994